Form 4: Surrozen EVP Granted Significant Equity Awards

Surrozen, Inc.'s Executive Vice President of Research, Yang Li, was granted 100,950 employee stock options and 100,950 restricted stock units, aligning executive incentives with long-term company performance.

Summary

• Yang Li, Executive Vice President of Research at Surrozen, Inc. (SRZN), was granted 100,950 employee stock options on February 17, 2026.
• These options have an exercise price of $24.53 and an expiration date of February 16, 2036.
• The options vest over a four-year period in 48 equal monthly installments, commencing February 1, 2026, contingent on continued service.
• Additionally, Li was granted 100,950 Restricted Stock Units (RSUs) on February 17, 2026.
• Each RSU represents a contingent right to receive one share of Surrozen's common stock.
• The RSUs vest in four equal annual installments, also starting on February 1, 2026, subject to continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signals strong alignment between executive incentives and long-term shareholder value, which is generally favorable for corporate governance and performance.

Positives

• The significant equity grants to a key executive, Yang Li, align management's long-term interests with shareholder value creation.
• The vesting schedules for both options and RSUs, extending over four years, incentivize long-term commitment and performance from the Executive Vice President of Research.
• The grants demonstrate the company's commitment to retaining and motivating key scientific leadership.

Negatives

• The grants represent potential future dilution for existing shareholders if the options are exercised and RSUs vest, though this is standard practice for executive compensation.

Risks

• The value of the equity awards is contingent on the company's future stock performance, which is subject to market risks and the success of Surrozen's research and development efforts.
• The vesting schedule requires continued service, meaning the executive must remain with the company for the full four years to realize the full benefit of the awards.

Future Outlook

The equity grants are structured to incentivize long-term performance and retention of a key executive, suggesting a focus on future research and development success.

Industry Context

StockSavvy.ai notes that equity grants, particularly to key research executives in the biotechnology sector, are a common mechanism to align leadership incentives with the long-term, high-risk, high-reward nature of drug development. Such grants are crucial for retaining talent in a competitive industry where intellectual capital is paramount.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of stock options and restricted stock units with multi-year vesting schedules, is a common practice for executive compensation in the biotechnology industry, comparable to compensation packages observed at peer companies like Moderna (MRNA) or BioNTech (BNTX) for their research leadership, aiming to incentivize long-term innovation and retention.

Stakeholder Impact

• Shareholders: Potential long-term benefit from incentivized executive performance, but also potential future dilution from option exercise and RSU vesting.
• Employees: May signal a positive compensation strategy for key personnel, potentially boosting morale and retention for other high-value employees.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation through equity grants. While it aligns management incentives with long-term shareholder value, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold and monitor broader company developments.

Keywords

Surrozen Inc., SRZN, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation, Equity Grant, Yang Li, Biotechnology